Dissolution and pharmacokinetics of baicalin–polyvinylpyrrolidone coprecipitate
Open Access
- 20 September 2013
- journal article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 65 (11) , 1670-1678
Abstract
Objectives: Baicalin–polyvinylpyrrolidone coprecipitate was prepared with the aim of improving the dissolution and bioavailability of the baicalin. Methods: The dissolution of the coprecipitate in capsule form was tested and compared with baicalin active pharmaceutical ingredient (API) capsules. A sensitive high-performance liquid chromatography-ultraviolet detection method was established to determine the concentration of baicalin in plasma. The liquid–liquid extraction and solid phase extraction methods were used to pretreat the baicalin plasma sample. The pharmacokinetics of the coprecipitate capsules were tested and compared with the API capsules in six beagle dogs after crossover oral administration. Key findings: The results of the dissolution demonstrated that the dissolution of the coprecipitate capsules was 21.02, 2.02 and 3.29 times that of the API capsules in 0.1 mol/l HCl solution, pH 4.5 solution and water, respectively, but it was slightly lower than that of the API capsules in a pH 6.8 solution. The calibration curve showed a good linearity at concentrations between 3.648 ng/mL and 364.8 ng/mL (r = 0.998). The baicalin plasma sample was successfully pretreated, with endogenous impurities almost completely removed. The pharmacokinetics of the coprecipitate capsules and the API capsules indicated that the mean values of Cmax were 127.04 ± 10.6 and 27.49 ± 36 μg/l, and those of AUC(0-24h) were 1080.23 ± 336.43 and 337.84 ± 127.64 μg/l × h, respectively. Compared with the baicalin API capsules, the relative bioavailability of the coprecipitate capsules was 338.2% ± 93.2%. Conclusions: From these observations of improved dissolution and pharmacokinetic behaviours, a good relationship was found in vitro and in vivo, indicating that the coprecipitate could be a promising formulation strategy for insoluble baicalin.Keywords
Funding Information
- National Natural Science Foundation of China (81171365)
This publication has 16 references indexed in Scilit:
- Pharmacological effects and pharmacokinetics properties ofRadix Scutellariaeand its bioactive flavonesBiopharmaceutics & Drug Disposition, 2011
- Preparation and characterization of baicalin-poly -vinylpyrrolidone coprecipitateInternational Journal of Pharmaceutics, 2011
- LC Determination and Pharmacokinetic Study of Hyperoside in Rat Plasma after Intravenous AdministrationYAKUGAKU ZASSHI, 2010
- Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectivesXenobiotica, 2010
- Design and evaluation of San-huang dispersible tablet – an efficient delivery system for Traditional Chinese MedicinePharmaceutical Development and Technology, 2009
- Protective effect of baicalin against Lipopolysaccharide/d-galactosamine-induced liver injury in mice by up-regulation of Heme oxygenase-1European Journal of Pharmacology, 2008
- Protective Effect of Baicalin Against Carbon Tetrachloride–Induced Acute Hepatic Injury in MiceJournal of Pharmacological Sciences, 2008
- Absorption and enterohepatic circulation of baicalin in ratsLife Sciences, 2005
- Hepatoprotective Effect of Baicalin, a Major Flavone fromScutellaria radix, on Acetaminophen‐Induced Liver Injury in MiceImmunopharmacology and Immunotoxicology, 2003
- Study on the bioavailability of baicalin-phospholipid complex by using HPLCBiomedical Chromatography, 1999